Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narmafotinib - Amplia Therapeutics

Drug Profile

Narmafotinib - Amplia Therapeutics

Alternative Names: AMP-945; CTX-0294945

Latest Information Update: 15 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Therapeutics CRC; Cytopia Inc
  • Developer Amplia Therapeutics
  • Class Acetamides; Amines; Antifibrotics; Antineoplastics; Fluorinated hydrocarbons; Hepatoprotectants; Phenyl ethers; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Fibrosis; Non-alcoholic steatohepatitis; Ovarian cancer
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 05 Apr 2024 Adverse events, efficacy and pharmacokinetics data from the phase-Ib/IIa trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 29 Mar 2024 Efficacy data from a phase Ia/IIb trial in Pancreatic cancer released by Amplia Therapeutics
  • 18 Jan 2024 Phase-II clinical trials in Pancreatic cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in Australia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top